First Mercantile Trust Co. grew its position in Quanterix Co. (NASDAQ:QTRX) by 58.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,920 shares of the company’s stock after acquiring an additional 710 shares during the quarter. First Mercantile Trust Co.’s holdings in Quanterix were worth $113,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in QTRX. Eaton Vance Management acquired a new position in shares of Quanterix in the 1st quarter valued at about $25,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Quanterix in the 1st quarter valued at about $87,000. Cutler Group LP acquired a new position in Quanterix during the 2nd quarter worth approximately $87,000. US Bancorp DE lifted its position in Quanterix by 103.1% during the 2nd quarter. US Bancorp DE now owns 1,489 shares of the company’s stock worth $87,000 after acquiring an additional 756 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its position in Quanterix by 68.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 1,583 shares of the company’s stock worth $92,000 after acquiring an additional 646 shares in the last quarter. 82.12% of the stock is currently owned by institutional investors and hedge funds.
In other Quanterix news, CEO E Kevin Hrusovsky sold 5,000 shares of Quanterix stock in a transaction that occurred on Tuesday, July 13th. The stock was sold at an average price of $57.45, for a total transaction of $287,250.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP David C. Duffy sold 1,667 shares of the business’s stock in a transaction that occurred on Wednesday, June 23rd. The shares were sold at an average price of $62.11, for a total value of $103,537.37. The disclosure for this sale can be found here. Insiders have sold a total of 17,817 shares of company stock worth $998,631 over the last 90 days. 15.40% of the stock is owned by company insiders.
Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.01). Quanterix had a negative return on equity of 8.76% and a negative net margin of 26.90%. The business had revenue of $25.37 million for the quarter, compared to analysts’ expectations of $23.59 million. Equities research analysts anticipate that Quanterix Co. will post -1.23 EPS for the current fiscal year.
Several equities analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Quanterix in a research report on Friday, June 4th. They set a “sell” rating and a $53.00 price target on the stock. SVB Leerink reissued a “buy” rating on shares of Quanterix in a research report on Thursday, June 10th. Finally, Canaccord Genuity reduced their price target on Quanterix from $90.00 to $75.00 and set a “buy” rating on the stock in a research report on Thursday, August 5th.
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development.
Featured Story: What are the advantages of the Stochastic Momentum Index?
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRX).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.